#Germany #Morphic Medical #Endoscopic Device #RESET Therapy

Morphic Medical Achieves NUB Status One for RESET® Therapy in Germany

Morphic Medical, a pioneering company in the development of innovative medical devices, has recently announced that it has achieved NUB (Neue Untersuchungs- und Behandlungsmethoden) Status One for its RESET® endoscopic therapy in Germany. This significant milestone allows healthcare institutions to seek additional reimbursement for the use of this groundbreaking device, ultimately promoting broader adoption and facilitating near-term commercial rollout.

Overview of RESET® Therapy

RESET® is designed specifically for individuals suffering from obesity and metabolic conditions such as Type 2 Diabetes. Unlike traditional surgical methods, this therapy is minimally invasive, providing an incision-free solution that aims to deliver both immediate weight loss and improved metabolic health. By targeting the root causes of obesity, RESET® offers hope for effective treatment options in a landscape that has long been dominated by more invasive procedures.

The attainment of NUB status signifies a vital moment in the therapy's journey within the German healthcare system. This designation means that RESET® is now officially recognized as a treatment backed by substantial clinical evidence, making it eligible for hospitals to apply for supplementary reimbursements. The distinction not only reflects confidence in the therapy but also serves as a catalyst for ongoing discussions about reimbursement strategies with medical institutions across Germany.

Importance of Clinical Evidence

Morphic Medical's CEO, Mike Gutteridge, emphasized the importance of this milestone. By stating, “This NUB recognition is an important milestone for Morphic Medical and for patients and hospitals seeking evidence-based, endoscopic metabolic therapies,” he highlights that the acknowledgment stems from a comprehensive body of clinical studies. The data supporting RESET® includes numerous peer-reviewed publications, real-world registry analyses, and clinical experiences gathered from leading researchers in the field of obesity treatment.

By relying on such credible evidence, Morphic Medical reaffirms its commitment to transparency and the advancement of healthcare solutions that are not only effective but also adhere to the highest medical standards.

Future Steps for Morphic Medical

With the NUB status now in effect, Morphic Medical is poised to collaborate with leading hospitals throughout Germany to support specific NUB applications. This partnership aims to foster clinical adoption while emphasizing the importance of continuous post-market clinical follow-up and registry participation.

The company is dedicated to generating further evidence, which is necessary for long-term reimbursement strategies and inclusion within clinical guidelines. In doing so, Morphic Medical hopes to solidify RESET®'s position as a clinically valuable therapy, ultimately benefitting countless patients battling obesity and metabolic disorders.

About Morphic Medical

Founded in 2003 and headquartered in Boston, Massachusetts, Morphic Medical is dedicated to developing alternative treatment options for morbid obesity and its related metabolic risk factors, such as Type 2 Diabetes and dyslipidemia. Although RESET® is not yet available for commercial sale in the United States, its investigational use demonstrates Morphic Medical's commitment to innovative healthcare solutions. For more information about their groundbreaking approach and future developments, visit morphicmedical.com or connect with them on Twitter and LinkedIn.

By achieving this NUB Status One, Morphic Medical is taking significant strides toward revolutionizing treatment methodologies for metabolic disorders, showcasing the potential of endoscopic innovations in healthcare today.